Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BYJournal of ovarian research

Systemic immune and coagulation amplifiers resolve diagnostic ambiguity in endometriosis-associated ovarian cancer.

4 affiliations
  1. 1Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. [email protected].
  2. 2Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  3. 3School of Medicine, Xiamen University, Xiamen, China.
  4. 4Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. [email protected].

Abstract

Background

Preoperative discrimination between endometriosis-associated ovarian cancer (EAOC) and benign ovarian endometrioma (OE) remains challenging because imaging findings overlap and CA125 is frequently elevated by benign pelvic inflammation. We hypothesized that EAOC is associated with a systemic immune-coagulation signature that could improve risk stratification beyond tumor markers alone.Methods

We retrospectively analyzed treatment-naive patients who underwent primary surgery for ovarian masses between January 2015 and February 2025. EAOC (n = 49) and OE (n = 146) were confirmed histopathologically according to the Sampson-Scott criteria. Preoperative laboratory indices obtained within 2 weeks before surgery included fibrinogen, albumin, absolute monocyte count (AMC), CA125, and HE4; the fibrinogen-to-albumin ratio (FAR) was calculated. A multivariable logistic regression model integrating age, menopausal status, AMC, FAR, CA125, and HE4 was developed as the CO-MHF nomogram. Supplementary data-driven analyses included least absolute shrinkage and selection operator (LASSO) logistic regression, Akaike information criterion (AIC)-based stepwise selection, and add-one/drop-one marginal contribution analysis. Discrimination, calibration, and clinical utility were assessed by area under the receiver operating characteristic curve (AUC), bootstrap-derived confidence interval (CI), the Hosmer-Lemeshow test, and decision curve analysis (DCA).Results

FAR and AMC were significantly higher in EAOC than in OE (median FAR 0.10 versus 0.07; median AMC 0.39 versus 0.31 × 10⁹/L). The CO-MHF model showed favorable internal discrimination (AUC 0.932, 95% CI 0.887-0.968), outperforming HE4 (0.835), FAR (0.786), CA125 (0.769), and AMC (0.657). At the Youden-derived threshold (0.468), sensitivity was 75.5% and specificity 95.9%, with a positive predictive value (PPV) of 86.0% and a negative predictive value (NPV) of 92.1%. Lower thresholds increased sensitivity to 85.7%-93.9% at the cost of reduced specificity. Supplementary data-driven analyses supported the predictor set: AIC-based stepwise selection identified the same variables, and LASSO retained all CO-MHF predictors. Calibration was acceptable (Hosmer-Lemeshow P = 0.225), and DCA showed greater net benefit across a range of threshold probabilities.Conclusions

A mechanism-informed nomogram combining FAR and AMC with established tumor markers may improve preoperative risk stratification for EAOC. This host-response framework merits further evaluation in other malignancy-versus-inflammation diagnostic settings, although prospective multicenter validation and clinical threshold optimization remain necessary.

Related

  1. Diagnostic challenge in distinguishing intestinal endometriosis-associated carcinoma from primary colorectal adenocarcinoma: a case report
    Norie Tojo, Hisashi Kataoka, Yuko Izumi +2
    Journal of Surgical Case ReportsPeer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
  2. Correlation between coagulation abnormalities and in vitro fertilization outcomes in infertile patients with endometriosis: a retrospective cohort study
    Xiufang Du, Wenjing Hu, Changna Fu
    Frontiers in MedicinePeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsDOAJEurope PMC
  3. Integrating disulfidptosis patterns and machine learning identifies a novel diagnostic signature for endometriosis
    Qingqing Li, Boen Zhao, Yulin Yuan +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsCrossref
  4. Diagnostic ambiguity and in-hospital mortality determinants: a decadal analysis of interstitial lung disease hospitalization trends in Ecuador (2015-2024).
    Karime Montes-Escobar, Cristian Cornejo Gaete, Carlos A Salas-Macias +2
    BMC pulmonary medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  5. Synovial Sarcoma of the Tibial Nerve in the Distal Leg: A Case of Diagnostic Ambiguity and Multimodal Management Protocol for Limb Salvage and Nerve Reconstruction - A Case Report
    Varun R Mehta, Rajkumar Mehta, Rahul Parmar +1
    Journal of Orthopaedic Case ReportsPeer-reviewedCC BY-NCFull textOncologyDOAJEurope PMC
BibTeX
@article{luo2026systemic,
  title = {{Systemic immune and coagulation amplifiers resolve diagnostic ambiguity in endometriosis-associated ovarian cancer.}},
  author = {Li Luo and Yanwei Tu and Zirui Zhu and Mingzhu Ye},
  journal = {Journal of ovarian research},
  year = {2026},
  month = jul,
  doi = {10.1186/s13048-026-02205-8},
  url = {https://europepmc.org/article/MED/42902392},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Systemic immune and coagulation amplifiers resolve diagnostic ambiguity in endometriosis-associated ovarian cancer.
AU  - Li Luo
AU  - Yanwei Tu
AU  - Zirui Zhu
AU  - Mingzhu Ye
PY  - 2026
DA  - 2026/07/01
JO  - Journal of ovarian research
DO  - 10.1186/s13048-026-02205-8
UR  - https://europepmc.org/article/MED/42902392
AB  - Background  Preoperative discrimination between endometriosis-associated ovarian cancer (EAOC) and benign ovarian endometrioma (OE) remains challenging because imaging findings overlap and CA125 is frequently elevated by benign pelvic inflammation. We hypothesized that EAOC is associated with a systemic immune-coagulation signature that could improve risk stratification beyond tumor markers alone.Methods  We retrospectively analyzed treatment-naive patients who underwent primary surgery for ovarian masses between January 2015 and February 2025. EAOC (n = 49) and OE (n = 146) were confirmed histopathologically according to the Sampson-Scott criteria. Preoperative laboratory indices obtained within 2 weeks before surgery included fibrinogen, albumin, absolute monocyte count (AMC), CA125, and HE4; the fibrinogen-to-albumin ratio (FAR) was calculated. A multivariable logistic regression model integrating age, menopausal status, AMC, FAR, CA125, and HE4 was developed as the CO-MHF nomogram. Supplementary data-driven analyses included least absolute shrinkage and selection operator (LASSO) logistic regression, Akaike information criterion (AIC)-based stepwise selection, and add-one/drop-one marginal contribution analysis. Discrimination, calibration, and clinical utility were assessed by area under the receiver operating characteristic curve (AUC), bootstrap-derived confidence interval (CI), the Hosmer-Lemeshow test, and decision curve analysis (DCA).Results  FAR and AMC were significantly higher in EAOC than in OE (median FAR 0.10 versus 0.07; median AMC 0.39 versus 0.31 × 10⁹/L). The CO-MHF model showed favorable internal discrimination (AUC 0.932, 95% CI 0.887-0.968), outperforming HE4 (0.835), FAR (0.786), CA125 (0.769), and AMC (0.657). At the Youden-derived threshold (0.468), sensitivity was 75.5% and specificity 95.9%, with a positive predictive value (PPV) of 86.0% and a negative predictive value (NPV) of 92.1%. Lower thresholds increased sensitivity to 85.7%-93.9% at the cost of reduced specificity. Supplementary data-driven analyses supported the predictor set: AIC-based stepwise selection identified the same variables, and LASSO retained all CO-MHF predictors. Calibration was acceptable (Hosmer-Lemeshow P = 0.225), and DCA showed greater net benefit across a range of threshold probabilities.Conclusions  A mechanism-informed nomogram combining FAR and AMC with established tumor markers may improve preoperative risk stratification for EAOC. This host-response framework merits further evaluation in other malignancy-versus-inflammation diagnostic settings, although prospective multicenter validation and clinical threshold optimization remain necessary.
SN  - 1757-2215
ER  -